阿戈美拉汀聯(lián)合認知行為干預對缺血性腦卒中后抑郁患者再發(fā)腦卒中的影響
發(fā)布時間:2019-07-11 18:47
【摘要】:目的探討阿戈美拉汀聯(lián)合認知行為干預對缺血性腦卒中后抑郁患者再發(fā)腦卒中的影響。方法首次診斷治療的腦卒中后抑郁患者114例隨機分為對照組和觀察組各57例。對照組采用艾司西酞普蘭配合認知行為干預,觀察組服用阿戈美拉汀聯(lián)合認知行為干預,兩組均治療3個月并配合完成6個月隨訪。觀察記錄兩組腦卒中再發(fā)率及治療前后漢密爾頓抑郁(HAMD)評分、副反應量表(TESS)評分。結(jié)果治療后,兩組HAMD評分均顯著改善,且觀察組改善效果顯著優(yōu)于對照組(P0.05)。對照組腦卒中再發(fā)率(17.54%)顯著高于觀察組(8.77%)(P0.05)。兩組用藥后均出現(xiàn)不良反應,觀察組激越、出汗發(fā)生率明顯少于對照組,且觀察組TESS評分〔(3.15±0.98)分〕顯著低于對照組〔(4.02±1.05)分〕(均P0.05)。結(jié)論阿戈美拉汀配合認知行為干預對腦卒中后抑郁患者具有較好的抗抑郁及神經(jīng)保護作用,且不良反應較少,安全性好。
[Abstract]:Objective to investigate the effect of agometine combined with cognitive behavior intervention on recurrent stroke in patients with post-ischemic stroke depression. Methods 114 patients with post-stroke depression diagnosed and treated for the first time were randomly divided into control group (n = 57) and observation group (n = 57). The control group was treated with escitalopram combined with cognitive behavior intervention, and the observation group was treated with agometine combined with cognitive behavior intervention. Both groups were treated for 3 months and followed up for 6 months. The recurrence rate of stroke, Hamilton depression (HAMD) score and side effect scale (TESS) score before and after treatment were observed and recorded. Results after treatment, the HAMD scores of the two groups were significantly improved, and the improvement effect of the observation group was significantly better than that of the control group (P 0.05). The recurrence rate of stroke in the control group (17.54%) was significantly higher than that in the observation group (8.77%) (P 0.05). The incidence of sweating in the observation group was significantly lower than that in the control group, and the TESS score in the observation group (3.15 鹵0.98) was significantly lower than that in the control group (4.02 鹵1.05) (P 0.05). Conclusion Agomelatine combined with cognitive behavior intervention has good antidepressant and neuroprotective effects on post-stroke depression patients, and the adverse reactions are less and the safety is good.
【作者單位】: 海南省安寧醫(yī)院;
【基金】:海南省自然科學基金項目(No.812163)
【分類號】:R749.13
本文編號:2513389
[Abstract]:Objective to investigate the effect of agometine combined with cognitive behavior intervention on recurrent stroke in patients with post-ischemic stroke depression. Methods 114 patients with post-stroke depression diagnosed and treated for the first time were randomly divided into control group (n = 57) and observation group (n = 57). The control group was treated with escitalopram combined with cognitive behavior intervention, and the observation group was treated with agometine combined with cognitive behavior intervention. Both groups were treated for 3 months and followed up for 6 months. The recurrence rate of stroke, Hamilton depression (HAMD) score and side effect scale (TESS) score before and after treatment were observed and recorded. Results after treatment, the HAMD scores of the two groups were significantly improved, and the improvement effect of the observation group was significantly better than that of the control group (P 0.05). The recurrence rate of stroke in the control group (17.54%) was significantly higher than that in the observation group (8.77%) (P 0.05). The incidence of sweating in the observation group was significantly lower than that in the control group, and the TESS score in the observation group (3.15 鹵0.98) was significantly lower than that in the control group (4.02 鹵1.05) (P 0.05). Conclusion Agomelatine combined with cognitive behavior intervention has good antidepressant and neuroprotective effects on post-stroke depression patients, and the adverse reactions are less and the safety is good.
【作者單位】: 海南省安寧醫(yī)院;
【基金】:海南省自然科學基金項目(No.812163)
【分類號】:R749.13
【相似文獻】
相關(guān)期刊論文 前1條
1 許瑞芹;李旭;胡慶秀;;強迫障礙病人的認知行為干預效果觀察[J];全科護理;2012年19期
,本文編號:2513389
本文鏈接:http://sikaile.net/yixuelunwen/jsb/2513389.html
最近更新
教材專著